Beyond the Pain: Rethinking Migraine Care with the RELIEF PLAN Approach

Article information

Headache Pain Res. 2025;.hpr.2024.0035
Publication date (electronic) : 2025 February 17
doi : https://doi.org/10.62087/hpr.2024.0035
Dr. Ryu’s Neurology Clinic, Busan, Republic of Korea
Correspondence: Sanghyo Ryu, M.D. Dr. Ryu’s Neurology Clinic, 240 Suyeong-ro, Nam-gu, Busan 48495, Republic of Korea Tel: +82-051-710-8881, Fax: 82-051-710-8188, E-mail: agapelive@naver.com
Received 2024 December 23; Revised 2025 January 14; Accepted 2025 January 15.

Recent articles in this issue of Headache and Pain Research have shed light on the complex nature of migraine, highlighting the need for a multifaceted approach to its understanding and management.1 Migraine affects approximately 1.1 billion people worldwide and continues to be one of the most disabling neurological conditions. The Global Burden of Disease studies have highlighted its substantial impact, ranking it as the second highest contributor to years lived with disability, with a particularly significant effect on women in their prime working years.2

Despite its significant contribution to disability-adjusted life years, especially among women and young adults, migraine frequently fails to receive the recognition given to other chronic conditions. This leads to its widespread trivialization and misunderstanding. The lack of awareness highlights the urgent need for improved public health initiatives aimed at enhancing understanding and recognition of the true impact of migraine.

The articles explore several dimensions of migraine pathology, treatment, and public perceptions. One study discusses the genetic, biological, and environmental factors contributing to migraine, supporting the view that migraine is not merely a headache but a complex disorder requiring a biopsychosocial approach for effective management. This aligns with the growing body of evidence linking potentially traumatic experiences occurring before the age of 18, including abuse, neglect, or household dysfunction, with the development of chronic migraines.3

Another contribution examines the evolution of migraine treatment, moving from the vascular theory to recognizing neural circuit dysfunction as the primary factor. The discovery of key players, such as calcitonin gene-related peptide, in migraine mechanisms has transformed therapeutic strategies, emphasizing the need for early detection and intervention to prevent progression to chronic or medication-overuse headaches.

In Korea, cultural and linguistic barriers complicate the recognition of migraines. An article addresses the term “편두통” (one-sided headache), which contributes to widespread misunderstandings about the nature of migraines. It cites a survey that shows a significant portion of the population harbors misconceptions about the characteristics and treatment of migraines, underscoring the need for improved public education.4

To address these issues, I propose the “RELIEF PLAN” approach to migraine management:

• R – Recognize adverse childhood events: Acknowledge the role of early trauma.3

• E – Educate the family: To change perceptions and provide support.4

• L – Lifestyle modifications: Incorporate non-pharmacological interventions.4

• I – Identify triggers: Tailor trigger management to the individual.4

• E – Early detection and intervention: Prevent chronicity through timely action.4

• F – Foster regular visits: Ensure ongoing care and research participation.4

• P – Plan for the future: Develop strategies to reduce societal burden.4

This editorial advocates for a future in which migraines are treated with the complexity and attention they deserve. It is informed by the latest research published in this issue, which calls for a holistic approach to care, education, and policy.

Notes

AVAILABILITY OF DATA AND MATERIAL

Not applicable.

AUTHOR CONTRIBUTIONS

Conceptualization: SR; Writing–review & editing: SR.

CONFLICT OF INTEREST

Sanghyo Ryu is the English editor of Headache and Pain Research and was not involved in the review process of this article. Author has no other conflicts of interest to declare.

FUNDING STATEMENT

Not applicable.

ACKNOWLEDGMENTS

Not applicable.

References

1. Kim BS, Chung PW, Chung JM, et al. Evidence-based recommendations on pharmacologic treatment for migraine prevention: a clinical practice guideline from the korean headache society. Headache Pain Res 2025;26:-------. 10.62087/hpr.2024.0019.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204–1222. 10.1016/s0140-6736(20)30925-9. 33069326.
3. Tietjen GE, Khubchandani J, Herial NA, Shah K. Adverse childhood experiences are associated with migraine and vascular biomarkers. Headache 2012;52:920–929. 10.1111/j.1526-4610.2012.02165.x. 22533684.
4. Kim BK, Chung YK, Kim JM, Lee KS, Chu MK. Prevalence, clinical characteristics and disability of migraine and probable migraine: a nationwide population-based survey in Korea. Cephalalgia 2013;33:1106–1116. 10.1177/0333102413484990. 23615490.

Article information Continued